These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

63 related items for PubMed ID: 1776840

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C.
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [Abstract] [Full Text] [Related]

  • 3. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
    Meffert M, Schomburg A, Hänninen EL, Menzel T, Vocke S, Dallmann I, Grosse J, Duensing S, Buer J, Kirchner H.
    Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M.
    Cancer Res; 1990 Oct 15; 50(20):6708-15. PubMed ID: 2208137
    [Abstract] [Full Text] [Related]

  • 6. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH.
    Eur J Cancer Clin Oncol; 1989 Oct 15; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J.
    Cancer J Sci Am; 1997 Dec 15; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC, Rosenberg SA.
    Cancer J Sci Am; 1997 Dec 15; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [Abstract] [Full Text] [Related]

  • 13. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM, Johnson B, Culley D, Shah R, Weber J, Venzon D, Yang JC, Linehan WM, Rosenberg SA.
    J Urol; 1998 Mar 15; 159(3):718-22. PubMed ID: 9474133
    [Abstract] [Full Text] [Related]

  • 14. Sequential liver and bone biochemical changes in hyperthyroidism: prospective controlled follow-up study.
    Huang MJ, Li KL, Wei JS, Wu SS, Fan KD, Liaw YF.
    Am J Gastroenterol; 1994 Jul 15; 89(7):1071-6. PubMed ID: 7912472
    [Abstract] [Full Text] [Related]

  • 15. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT, Osgood B, Barna B, Boyett JM, Finke J, Medendorp SV, Murthy S, Novak C, Sergi J, Tubbs R.
    Cancer Res; 1989 Nov 15; 49(22):6432-6. PubMed ID: 2804986
    [Abstract] [Full Text] [Related]

  • 16. Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection.
    Abi-Aad AS, Figlin RA, Belldegrun A, deKernion JB.
    J Immunother (1991); 1991 Aug 15; 10(4):292-5. PubMed ID: 1931865
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T.
    Cancer J Sci Am; 2000 Feb 15; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.
    Rev Med Univ Navarra; 1996 Feb 15; 40(3):6-12. PubMed ID: 9499820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.